PA8782901A1 - "nuevos compuestos ligandos del receptor de la adenosina a3" - Google Patents

"nuevos compuestos ligandos del receptor de la adenosina a3"

Info

Publication number
PA8782901A1
PA8782901A1 PA20088782901A PA8782901A PA8782901A1 PA 8782901 A1 PA8782901 A1 PA 8782901A1 PA 20088782901 A PA20088782901 A PA 20088782901A PA 8782901 A PA8782901 A PA 8782901A PA 8782901 A1 PA8782901 A1 PA 8782901A1
Authority
PA
Panama
Prior art keywords
compounds
isomers
oxides
salts
general formula
Prior art date
Application number
PA20088782901A
Other languages
English (en)
Spanish (es)
Inventor
Sandor Batori
Kinga Boer
Michel Finet
Zoltan Kapui
Endre Mikus
Edit Susan
Tibor Szabo
Zoltan Szlavik
Gesa Timari
Szabo Katalin Urban
Szeredi Judit Vargane
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PA8782901A1 publication Critical patent/PA8782901A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
PA20088782901A 2007-06-07 2008-06-05 "nuevos compuestos ligandos del receptor de la adenosina a3" PA8782901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU0700395A HUP0700395A2 (en) 2007-06-07 2007-06-07 Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates

Publications (1)

Publication Number Publication Date
PA8782901A1 true PA8782901A1 (es) 2009-01-23

Family

ID=89987565

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088782901A PA8782901A1 (es) 2007-06-07 2008-06-05 "nuevos compuestos ligandos del receptor de la adenosina a3"

Country Status (45)

Country Link
US (1) US8338411B2 (pl)
EP (1) EP2167470B1 (pl)
JP (1) JP5487100B2 (pl)
KR (1) KR20100031610A (pl)
CN (1) CN101679272B (pl)
AR (1) AR066873A1 (pl)
AT (1) ATE502016T1 (pl)
AU (1) AU2008259534B2 (pl)
BR (1) BRPI0812257A2 (pl)
CA (1) CA2689612A1 (pl)
CL (1) CL2008001648A1 (pl)
CO (1) CO6270233A2 (pl)
CR (1) CR11171A (pl)
CY (1) CY1111644T1 (pl)
DE (1) DE602008005589D1 (pl)
DK (1) DK2167470T3 (pl)
DO (1) DOP2009000276A (pl)
EC (1) ECSP099783A (pl)
ES (1) ES2363672T3 (pl)
GT (1) GT200900301A (pl)
HK (1) HK1138581A1 (pl)
HN (1) HN2009003357A (pl)
HR (1) HRP20110332T1 (pl)
HU (1) HUP0700395A2 (pl)
IL (1) IL202471A0 (pl)
JO (1) JO2689B1 (pl)
MA (1) MA31738B1 (pl)
ME (1) ME00958B (pl)
MX (1) MX2009013209A (pl)
MY (1) MY148654A (pl)
NI (1) NI200900210A (pl)
NZ (1) NZ581186A (pl)
PA (1) PA8782901A1 (pl)
PE (1) PE20090325A1 (pl)
PL (1) PL2167470T3 (pl)
PT (1) PT2167470E (pl)
RU (1) RU2489432C2 (pl)
SI (1) SI2167470T1 (pl)
SV (1) SV2009003420A (pl)
TN (1) TN2009000482A1 (pl)
TW (1) TWI424998B (pl)
UA (1) UA99463C2 (pl)
UY (1) UY31130A1 (pl)
WO (1) WO2008149168A1 (pl)
ZA (1) ZA200908280B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2451796T3 (da) 2009-07-08 2013-07-29 Dermira Canada Inc Tofaanaloger til behandling af dermatologiske lidelser eller tilstande
FR3053968A1 (fr) 2016-07-13 2018-01-19 Biomerieux Reactifs pour la protection reversible de molecules biologiques
MY195054A (en) 2016-09-24 2023-01-05 Kbp Biosciences Co Ltd Pharmaceutical Composition Comprising Mineralocorticoid Receptor Antagonist and use Thereof
BR112020017421A2 (pt) 2018-02-27 2020-12-22 Incyte Corporation Imidazopirimidinas e triazolopirimidinas como inibidores de a2a/a2b
MA52940A (fr) 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
GEP20237560B (en) 2018-07-05 2023-10-25 Incyte Corp Fused pyrazine derivatives as a2a / a2b inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479759A (en) * 1974-11-23 1977-07-13 Lepetit Spa Heterocyclic fused derivatives of indole and quinoline
GR76063B (pl) * 1981-04-03 1984-08-03 Roussel Uclaf
ZA836701B (en) * 1982-10-01 1984-10-31 Roussel Uclaf Imidazo(1,2-a)quinolines
GB0108475D0 (en) 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
EE05304B1 (et) * 2001-05-31 2010-06-15 Sanofi-Synthlabo Aminokinoliini derivaadid, meetod nende valmistamiseks, neid sisaldavad ravimkoostised ja nende kasutamine adenosiini A3-retseptori ligandidena
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
NZ533682A (en) 2001-12-21 2007-06-29 Jsw Res Forschungslabor Gmbh Pyrazolyl-substituted triazoloquinoxalines
HUP0105407A3 (en) * 2001-12-21 2004-04-28 Sanofi Aventis Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0105406A3 (en) * 2001-12-21 2003-12-29 Sanofi Aventis Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0203976A3 (en) * 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
DE602004010284T2 (de) * 2003-07-31 2008-10-02 Sanofi-Aventis Aminochinolinderivate und deren verwendung als adenosin-a3-liganden

Also Published As

Publication number Publication date
EP2167470B1 (en) 2011-03-16
US20100216786A1 (en) 2010-08-26
KR20100031610A (ko) 2010-03-23
HUP0700395A2 (en) 2009-03-02
DE602008005589D1 (de) 2011-04-28
WO2008149168A8 (en) 2010-01-07
JP5487100B2 (ja) 2014-05-07
MX2009013209A (es) 2010-04-09
PL2167470T3 (pl) 2011-08-31
DK2167470T3 (da) 2011-06-27
RU2009149518A (ru) 2011-07-20
PT2167470E (pt) 2011-05-16
AR066873A1 (es) 2009-09-16
JP2010529100A (ja) 2010-08-26
CA2689612A1 (en) 2008-12-11
AU2008259534A1 (en) 2008-12-11
UA99463C2 (en) 2012-08-27
US8338411B2 (en) 2012-12-25
DOP2009000276A (es) 2010-01-31
JO2689B1 (en) 2013-03-03
TW200914451A (en) 2009-04-01
GT200900301A (es) 2010-04-22
AU2008259534B2 (en) 2012-07-05
TWI424998B (zh) 2014-02-01
ES2363672T3 (es) 2011-08-11
UY31130A1 (es) 2009-01-30
MA31738B1 (fr) 2010-10-01
CN101679272A (zh) 2010-03-24
EP2167470A1 (en) 2010-03-31
HU0700395D0 (en) 2007-07-30
SV2009003420A (es) 2010-04-26
HK1138581A1 (en) 2010-08-27
NZ581186A (en) 2012-03-30
CL2008001648A1 (es) 2008-10-10
HN2009003357A (es) 2013-08-12
CY1111644T1 (el) 2015-10-07
ZA200908280B (en) 2010-07-28
ATE502016T1 (de) 2011-04-15
HRP20110332T1 (hr) 2011-06-30
RU2489432C2 (ru) 2013-08-10
ECSP099783A (es) 2010-01-29
ME00958B (me) 2012-06-20
BRPI0812257A2 (pt) 2014-12-23
CO6270233A2 (es) 2011-04-20
SI2167470T1 (sl) 2011-06-30
CR11171A (es) 2010-04-21
PE20090325A1 (es) 2009-04-17
WO2008149168A1 (en) 2008-12-11
MY148654A (en) 2013-05-15
IL202471A0 (en) 2010-06-30
CN101679272B (zh) 2013-02-06
TN2009000482A1 (en) 2011-03-31
NI200900210A (es) 2010-07-15

Similar Documents

Publication Publication Date Title
PA8782901A1 (es) "nuevos compuestos ligandos del receptor de la adenosina a3"
NI200900032A (es) Compuestos de pirido (2, 3-d) pirimidinonay su uso como inhibidores de pi3
UY29798A1 (es) Derivados de carboxamida como antagonistas del receptor muscarínico
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
UY29886A1 (es) Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones
PH12012502284A1 (en) Antiviral nucleoside analogs
DOP2011000171A (es) Compuestos organico
CR20120264A (es) Compuestos
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
SV2010003580A (es) Agonistas novedosos de los receptores de glucocorticoides
ECSP088584A (es) Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl)
UY31048A1 (es) Nuevos compuestos de pirimidina y usos de los mismos
GT200600144A (es) 1h-quinazolin-2,4-dionas
CO6351723A2 (es) Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1
CO6531479A2 (es) Derivados de espirolactama y uso de los mismos
CR11828A (es) Compuestos novedosos activos como antagonistas de receptor muscarínico
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
ECSP10010200A (es) Derivados de pirazol como inhibidores de 5-lo
CR9595A (es) Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona
ECSP099679A (es) Nuevos compuestos y sus usos 707
UY31338A1 (es) Compuestos novedosos activos como antagonistas de receptores muscarinicos
AR069009A1 (es) Arilindenopirimidinas y su uso como antagonistas del receptor a₂a de adenosina
PA8764701A1 (es) S-nitrosotioles estables, procedimiento de síntesis y uso
CU23564A3 (es) Derivados de carboxamida como antagonistas del receptor muscarínico